Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of mTOR signaling in the antidepressant effect of ketamine
2013-000952-17Phase 3Completed
- Sponsor
- National Institute of Mental Health, Czech Republic
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by National Institute of Mental Health, Czech Republic. Primary endpoint: Primary hypothesis (mTOR pathway differences between responders and non-responders). Started Mar 2013; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2013-000952-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000952-17.